BioMaxima S.A. (WSE: BMX)

Market Cap	59.12M
Revenue (ttm)	48.97M
Net Income (ttm)	-454.00K
Shares Out	4.19M
EPS (ttm)	-0.11
PE Ratio	n/a
Forward PE	n/a
Dividend	0.39 (2.77%)
Ex-Dividend Date	n/a

Volume	841
Open	14.05
Previous Close	14.10
Day's Range	14.00 - 14.20
52-Week Range	12.16 - 20.50
Beta	-2.46
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 29, 2024

About BioMaxima

BioMaxima S.A. manufactures and distributes microbiological media, reagents, and equipment for in vitro diagnostics in Poland. Its primary products include analyzers and diagnostic reagents for testing the biochemical parameters of blood and other body fluids; systems for the determination of drug resistance of microorganisms; quick diagnostic tests for detecting infectious diseases, cancer markers, heart attack markers, and addictive substances and readers; urine analysis systems; hematology analyzers and reagents; ionselective analyzers and r...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1997
• Employees: 115
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: BMX

Financial Performance

In 2023, BioMaxima's revenue was 46.79 million, a decrease of -67.48% compared to the previous year's 143.87 million. Earnings were 586,000, a decrease of -97.97%.